Drug Type Small molecule drug |
Synonyms KC 1036, KC-1036 |
Target |
Action inhibitors, antagonists |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H31F2N3O7 |
InChIKeyPCKYITPVOLEZKL-UHFFFAOYSA-N |
CAS Registry2222730-78-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | China | 26 Jan 2024 | |
Ewing Sarcoma | Phase 2 | China | 27 Sep 2024 | |
thymic carcinoma | Phase 2 | China | 22 Feb 2023 | |
Metastatic thymic carcinoma | Phase 2 | China | 07 Feb 2023 | |
Recurrent Thymic Carcinoma | Phase 2 | China | 07 Feb 2023 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | China | 17 May 2022 | |
Metastatic Solid Tumor | Phase 2 | China | 17 May 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 28 Aug 2020 | |
Advanced Lung Adenocarcinoma | IND Approval | China | 11 Jan 2023 | |
Hematologic Neoplasms | IND Application | China | 20 Nov 2019 |
Phase 2 | 58 | apzrexdpsw(nwammhnlpz) = zqmlyzyqqp vjoukzhyxh (bwbivudaob, 12.6 - 51.1) View more | Positive | 31 May 2023 | |||
Phase 1 | 41 | atktfaildi(hwiotolkby) = 60 mg QD gythatjxit (speqfbungm ) | Positive | 26 May 2023 | |||
Phase 1 | - | vbgpbuefdh(rqpzadwwkp) = Diarrhea (10.8%) rsksaefpsy (qlyjvjkvao ) | Positive | 09 Jun 2022 |